Glucocorticoids are the cornerstone treatment for polymyalgia rheumatica but induce adverse
events. The efficacy of the candidate drug tofacitinib has not yet been demonstrated in
controlled studies. The aim of the study is to compare the efficacy and safety of tofacitinib
as a glucocorticoid sparing agent in patients with refractory polymyalgia rheumatica.